Vandetanib
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071769
CAS NO.443913-73-3
Purity 95% MDL NumberMFCD07772346
Molecular FormulaC22H24BrFN4O2
Molecular Weight475.36
Melting point: 240 – 243°C
| Item | Information |
|---|---|
| Mechanism of Action | Vandetanib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), RET, and VEGFR families. It inhibits tumor growth and angiogenesis by blocking these receptors. |
| Indications | – Treatment of locally advanced or metastatic medullary thyroid cancer (MTC) in adults.<br>- Investigational use in non-small cell lung cancer (NSCLC) and other solid tumors. |
| Dosage Forms | Available as oral tablets. |
| Common Side Effects | Diarrhea, rash, nausea, hypertension, decreased appetite, fatigue, headache, vomiting, and blurred vision. |
| Serious Side Effects | QT prolongation, interstitial lung disease, heart failure, bleeding, stroke, reversible posterior leukoencephalopathy syndrome (RPLS), slow wound healing. |
| Special Precautions | – Regular monitoring of heart function (EKG), blood pressure, and thyroid function.<br>- Avoid sun exposure and use sunscreen to reduce risk of skin reactions.<br>- Women and men of reproductive potential should use effective contraception during treatment and for at least 4 months after the last dose.<br>- Avoid concomitant use with other drugs that may prolong QT interval. |
| Storage Conditions | Store at room temperature, protected from light and moisture |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
